Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

被引：1
|
作者：
Croop, Robert [1 ]
Ailani, Jessica [2 ]
Kudrow, David
Smith, Timothy [3 ]
Lipton, Richard [4 ]
Thiry, Alexandra [1 ]
Jensen, Christopher [1 ]
Kamen, Lisa [1 ]
机构：
[1] Biohaven Pharmaceut, New Haven, CT USA
[2] Medstar Georgetown Neurol, Washington, DC USA
[3] Study Metrix Res, St Petersburg, FL USA
[4] Albert Einstein Coll Med, New York, NY USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202051
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P10-12.010
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
    McElroy, SL
    Zarate, CA
    Cookson, J
    Suppes, T
    Huffman, RF
    Greene, P
    Ascher, J
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (02) : 204 - 210
  • [22] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: a 52-week open-label study
    Peters-Strickland, T.
    Baker, R. A.
    McQuade, R.
    Jin, N.
    Eramo, A.
    Perry, P.
    Johnson, B.
    Duca, A.
    Sanchez, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S542 - S542
  • [23] Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
    Joseph R. Calabrese
    Na Jin
    Brian Johnson
    Pedro Such
    Ross A. Baker
    Jessica Madera
    Peter Hertel
    Jocelyn Ottinger
    Joan Amatniek
    Hiroaki Kawasaki
    International Journal of Bipolar Disorders, 6
  • [24] Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
    Calabrese, Joseph R.
    Jin, Na
    Johnson, Brian
    Such, Pedro
    Baker, Ross A.
    Madera, Jessica
    Hertel, Peter
    Ottinger, Jocelyn
    Amatniek, Joan
    Kawasaki, Hiroaki
    INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS, 2018, 6
  • [25] Aripiprazole once-monthly for long-term maintenance treatment of schizophrenia: A 52-week open-label study
    Baker, R.
    Peters-Strickland, T.
    McQuade, R. D.
    Jin, N.
    Eramo, A.
    Perry, P. P.
    Johnson, B. R.
    Duca, A. R.
    Sanchez, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 64 - 64
  • [26] Ziprasidone in treatment-resistant schizophrenia: A 52-week, open-label continuation study
    Loebel, Antony D.
    Khanna, Surnant
    Rajadhyaksha, Sunita
    Siu, Cynthia O.
    Giller, Earl
    Potkin, Steven G.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (09) : 1333 - 1338
  • [27] Aripiprazole versus olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week open-label extension study
    Sanchez, R
    Kostic, D
    Stock, E
    Torbeyns, A
    Kerselaers, W
    Nyilas, M
    McQuade, R
    Carson, W
    Marcus, R
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 65 - 65
  • [28] A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
    Gopal, S.
    Vijapurkar, U.
    Lim, P.
    Morozova, M.
    Eerdekens, M.
    Hough, D.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (05) : 685 - 697
  • [29] Functional Recovery Among Patients With Schizophrenia Receiving Aripiprazole Once-Monthly in a 52-Week, Open-Label, Maintenance Study
    Madera, Jessica
    Liu, Sharon
    Peters-Strickland, Timothy
    Such, Pedro
    Baker, Ross A.
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S474 - S475
  • [30] Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study
    Labrie, Fernand
    Archer, David F.
    Bouchard, Celine
    Girard, Ginette
    Ayotte, Normand
    Gallagher, John C.
    Cusan, Leonello
    Baron, Mira
    Blouin, Francois
    Waldbaum, Arthur S.
    Koltun, William
    Portman, David J.
    Cote, Isabelle
    Lavoie, Lyne
    Beauregard, Adam
    Labrie, Claude
    Martel, Celine
    Balser, John
    Moyneur, Erick
    MATURITAS, 2015, 81 (01) : 46 - 56
12345